{"id":38421,"date":"2026-04-15T09:23:45","date_gmt":"2026-04-15T07:23:45","guid":{"rendered":"https:\/\/ggba.swiss\/?p=38421"},"modified":"2026-04-15T09:23:46","modified_gmt":"2026-04-15T07:23:46","slug":"ac-immune-secures-chf-10-million-from-lilly-to-advance-alzheimers-therapy","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/en\/ac-immune-secures-chf-10-million-from-lilly-to-advance-alzheimers-therapy\/","title":{"rendered":"AC Immune secures CHF 10 million from Lilly to advance Alzheimer&#8217;s therapy"},"content":{"rendered":"\n<p><a href=\"https:\/\/www.acimmune.com\">AC Immune SA<\/a>, the Lausanne-based clinical-stage biopharmaceutical company headquartered at the <a href=\"https:\/\/www.epfl-innovationpark.ch\">EPFL Innovation Park<\/a>, has announced an amendment to its 2018 license and collaboration agreement with <a href=\"https:\/\/www.lilly.com\">Eli Lilly and Company<\/a> for the research and development of Tau aggregation inhibitor small molecules. The amended agreement expands the collaboration to cover new lead Tau Morphomer candidates and potential back-up compounds, with IND (Investigational New Drug)-enabling studies expected to commence in the first half of 2026.<\/p>\n\n\n\n<p>AC Immune&#8217;s Morphomer platform develops small molecules selected for their ability to penetrate the brain when administered orally and to bind specifically to the pathological conformation of the Tau protein, a key driver of neurodegeneration in Alzheimer&#8217;s disease and related conditions. Strong preclinical data generated by AC Immune suggests that Tau Morphomers can inhibit aggregation and seeding across multiple pathological and disease stages, with growing scientific evidence indicating that targeting intracellular Tau may slow or halt disease pathology entirely.<\/p>\n\n\n\n<p>Under the amendment, AC Immune will receive a CHF 10 million upfront payment and a milestone payment upon Phase 1 dosing, in addition to previously announced milestones. The company remains eligible for further development, regulatory, and commercial milestones exceeding CHF 1.7 billion, plus tiered royalty payments in the low double digits.<\/p>\n\n\n\n<p>The Lilly collaboration is the latest in a series of high-value partnerships secured by AC Immune, whose track record includes a <a href=\"https:\/\/ggba.swiss\/en\/ac-immune-and-takeda-sign-usd-100-million-deal-to-treat-alzheimers-disease\/\">USD 100 million upfront agreement with Takeda<\/a> for its ACI-24.060 amyloid beta immunotherapy and <a href=\"https:\/\/ggba.swiss\/en\/ac-immune-receives-fda-fast-track-designation-for-alzheimers-disease-therapy\/\">FDA Fast Track designation for JNJ-2056<\/a>, its anti-Tau active immunotherapy developed with Janssen. The company&#8217;s pipeline now represents over USD 4.5 billion in potential milestone payments across its portfolio of therapeutic and diagnostic programs.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Lausanne-based AC Immune has amended its license and collaboration agreement with Eli Lilly to advance new Tau Morphomer small molecule candidates for Alzheimer&#8217;s disease and other neurodegenerative diseases, with IND-enabling studies set to commence in the first half of 2026.<\/p>\n","protected":false},"author":6,"featured_media":38422,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[833],"tags":[912,894,963,926,911,901],"class_list":["post-38421","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-life-science","tag-biotech","tag-financing","tag-medical-devices","tag-medtech","tag-pharma","tag-technology-park"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>AC Immune secures CHF 10 million from Lilly | GGBa<\/title>\n<meta name=\"description\" content=\"AC Immune has amended collaboration agreement with Eli Lilly to advance new Tau Morphomer small molecule candidates for Alzheimer&#039;s disease\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ggba.swiss\/en\/ac-immune-secures-chf-10-million-from-lilly-to-advance-alzheimers-therapy\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AC Immune secures CHF 10 million from Lilly | GGBa\" \/>\n<meta property=\"og:description\" content=\"AC Immune has amended collaboration agreement with Eli Lilly to advance new Tau Morphomer small molecule candidates for Alzheimer&#039;s disease\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ggba.swiss\/en\/ac-immune-secures-chf-10-million-from-lilly-to-advance-alzheimers-therapy\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-15T07:23:45+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-15T07:23:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ggba.swiss\/app\/uploads\/2026\/04\/AC-Immune-Morphomer-1180x811-1.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1180\" \/>\n\t<meta property=\"og:image:height\" content=\"811\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Pierre-Yves Oehrli\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pierre-Yves Oehrli\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ggba.swiss\/en\/ac-immune-secures-chf-10-million-from-lilly-to-advance-alzheimers-therapy\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ggba.swiss\/en\/ac-immune-secures-chf-10-million-from-lilly-to-advance-alzheimers-therapy\/\"},\"author\":{\"name\":\"Pierre-Yves Oehrli\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"headline\":\"AC Immune secures CHF 10 million from Lilly to advance Alzheimer&#8217;s therapy\",\"datePublished\":\"2026-04-15T07:23:45+00:00\",\"dateModified\":\"2026-04-15T07:23:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/en\/ac-immune-secures-chf-10-million-from-lilly-to-advance-alzheimers-therapy\/\"},\"wordCount\":281,\"image\":{\"@id\":\"https:\/\/ggba.swiss\/en\/ac-immune-secures-chf-10-million-from-lilly-to-advance-alzheimers-therapy\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2026\/04\/AC-Immune-Morphomer-1180x811-1.jpeg\",\"keywords\":[\"Biotech\",\"Financing\",\"Medical Devices\",\"Medtech\",\"Pharma\",\"Technology Park\"],\"articleSection\":[\"Life sciences\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ggba.swiss\/en\/ac-immune-secures-chf-10-million-from-lilly-to-advance-alzheimers-therapy\/\",\"url\":\"https:\/\/ggba.swiss\/en\/ac-immune-secures-chf-10-million-from-lilly-to-advance-alzheimers-therapy\/\",\"name\":\"AC Immune secures CHF 10 million from Lilly | GGBa\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/en\/ac-immune-secures-chf-10-million-from-lilly-to-advance-alzheimers-therapy\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ggba.swiss\/en\/ac-immune-secures-chf-10-million-from-lilly-to-advance-alzheimers-therapy\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2026\/04\/AC-Immune-Morphomer-1180x811-1.jpeg\",\"datePublished\":\"2026-04-15T07:23:45+00:00\",\"dateModified\":\"2026-04-15T07:23:46+00:00\",\"author\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"description\":\"AC Immune has amended collaboration agreement with Eli Lilly to advance new Tau Morphomer small molecule candidates for Alzheimer's disease\",\"breadcrumb\":{\"@id\":\"https:\/\/ggba.swiss\/en\/ac-immune-secures-chf-10-million-from-lilly-to-advance-alzheimers-therapy\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ggba.swiss\/en\/ac-immune-secures-chf-10-million-from-lilly-to-advance-alzheimers-therapy\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ggba.swiss\/en\/ac-immune-secures-chf-10-million-from-lilly-to-advance-alzheimers-therapy\/#primaryimage\",\"url\":\"https:\/\/ggba.swiss\/app\/uploads\/2026\/04\/AC-Immune-Morphomer-1180x811-1.jpeg\",\"contentUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2026\/04\/AC-Immune-Morphomer-1180x811-1.jpeg\",\"width\":1180,\"height\":811,\"caption\":\"AC Immune's Morphomer platform develops small molecules designed to enter the brain orally and bind specifically to pathological forms of the Tau protein, targeting a key driver of neurodegeneration in Alzheimer's disease and related conditions. | \u00a9 AC Immune\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ggba.swiss\/en\/ac-immune-secures-chf-10-million-from-lilly-to-advance-alzheimers-therapy\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ggba.swiss\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AC Immune secures CHF 10 million from Lilly to advance Alzheimer&#8217;s therapy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\",\"name\":\"Pierre-Yves Oehrli\",\"url\":\"https:\/\/ggba.swiss\/en\/author\/pierre-yves-oehrli\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AC Immune secures CHF 10 million from Lilly | GGBa","description":"AC Immune has amended collaboration agreement with Eli Lilly to advance new Tau Morphomer small molecule candidates for Alzheimer's disease","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ggba.swiss\/en\/ac-immune-secures-chf-10-million-from-lilly-to-advance-alzheimers-therapy\/","og_locale":"en_US","og_type":"article","og_title":"AC Immune secures CHF 10 million from Lilly | GGBa","og_description":"AC Immune has amended collaboration agreement with Eli Lilly to advance new Tau Morphomer small molecule candidates for Alzheimer's disease","og_url":"https:\/\/ggba.swiss\/en\/ac-immune-secures-chf-10-million-from-lilly-to-advance-alzheimers-therapy\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2026-04-15T07:23:45+00:00","article_modified_time":"2026-04-15T07:23:46+00:00","og_image":[{"width":1180,"height":811,"url":"https:\/\/ggba.swiss\/app\/uploads\/2026\/04\/AC-Immune-Morphomer-1180x811-1.jpeg","type":"image\/jpeg"}],"author":"Pierre-Yves Oehrli","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Pierre-Yves Oehrli","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ggba.swiss\/en\/ac-immune-secures-chf-10-million-from-lilly-to-advance-alzheimers-therapy\/#article","isPartOf":{"@id":"https:\/\/ggba.swiss\/en\/ac-immune-secures-chf-10-million-from-lilly-to-advance-alzheimers-therapy\/"},"author":{"name":"Pierre-Yves Oehrli","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"headline":"AC Immune secures CHF 10 million from Lilly to advance Alzheimer&#8217;s therapy","datePublished":"2026-04-15T07:23:45+00:00","dateModified":"2026-04-15T07:23:46+00:00","mainEntityOfPage":{"@id":"https:\/\/ggba.swiss\/en\/ac-immune-secures-chf-10-million-from-lilly-to-advance-alzheimers-therapy\/"},"wordCount":281,"image":{"@id":"https:\/\/ggba.swiss\/en\/ac-immune-secures-chf-10-million-from-lilly-to-advance-alzheimers-therapy\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2026\/04\/AC-Immune-Morphomer-1180x811-1.jpeg","keywords":["Biotech","Financing","Medical Devices","Medtech","Pharma","Technology Park"],"articleSection":["Life sciences"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/ggba.swiss\/en\/ac-immune-secures-chf-10-million-from-lilly-to-advance-alzheimers-therapy\/","url":"https:\/\/ggba.swiss\/en\/ac-immune-secures-chf-10-million-from-lilly-to-advance-alzheimers-therapy\/","name":"AC Immune secures CHF 10 million from Lilly | GGBa","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ggba.swiss\/en\/ac-immune-secures-chf-10-million-from-lilly-to-advance-alzheimers-therapy\/#primaryimage"},"image":{"@id":"https:\/\/ggba.swiss\/en\/ac-immune-secures-chf-10-million-from-lilly-to-advance-alzheimers-therapy\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2026\/04\/AC-Immune-Morphomer-1180x811-1.jpeg","datePublished":"2026-04-15T07:23:45+00:00","dateModified":"2026-04-15T07:23:46+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"description":"AC Immune has amended collaboration agreement with Eli Lilly to advance new Tau Morphomer small molecule candidates for Alzheimer's disease","breadcrumb":{"@id":"https:\/\/ggba.swiss\/en\/ac-immune-secures-chf-10-million-from-lilly-to-advance-alzheimers-therapy\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ggba.swiss\/en\/ac-immune-secures-chf-10-million-from-lilly-to-advance-alzheimers-therapy\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ggba.swiss\/en\/ac-immune-secures-chf-10-million-from-lilly-to-advance-alzheimers-therapy\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2026\/04\/AC-Immune-Morphomer-1180x811-1.jpeg","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2026\/04\/AC-Immune-Morphomer-1180x811-1.jpeg","width":1180,"height":811,"caption":"AC Immune's Morphomer platform develops small molecules designed to enter the brain orally and bind specifically to pathological forms of the Tau protein, targeting a key driver of neurodegeneration in Alzheimer's disease and related conditions. | \u00a9 AC Immune"},{"@type":"BreadcrumbList","@id":"https:\/\/ggba.swiss\/en\/ac-immune-secures-chf-10-million-from-lilly-to-advance-alzheimers-therapy\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/en\/"},{"@type":"ListItem","position":2,"name":"AC Immune secures CHF 10 million from Lilly to advance Alzheimer&#8217;s therapy"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41","name":"Pierre-Yves Oehrli","url":"https:\/\/ggba.swiss\/en\/author\/pierre-yves-oehrli\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/38421","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/comments?post=38421"}],"version-history":[{"count":1,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/38421\/revisions"}],"predecessor-version":[{"id":38425,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/38421\/revisions\/38425"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/media\/38422"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/media?parent=38421"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/categories?post=38421"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/tags?post=38421"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}